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introduction: During systemic sclerosis (SSc), peripheral B cells display alterations in 
subset homeostasis and functional properties and are a promising therapeutic target. 
However, there is only few data regarding whether these anomalies are accurately repro-
duced in animal models of SSc.
Objective: In this work, we assessed the B cell homeostasis modifications in an exper-
imental model of SSc [hypochlorous acid (HOCl)-induced mouse], both at a phenotypic 
and functional level, during the course of the disease.
Methods: Balb/c mice underwent daily intradermal injections of HOCl (or phos-
phate-buffered saline) and were then sacrificed at day 21 (early inflammatory stage) or 
day 42 (late fibrotic stage). For phenotypic studies, the distribution of the main spleen 
cell subsets (B cells, T CD4 and CD8 cells, NK cells, macrophages) and splenic B cell 
subsets (immature, mature naïve, germinal center, antibody-secreting, memory, B1) was 
assessed by flow cytometry. For functional studies, splenic B cells were immediately 
MACS-sorted. Production of interleukin (IL)-6, CCL3, IL-10, and transforming growth 
factor (TGF)-β was assessed ex vivo by RT-PCR and after 48 h of culture by ELISA. 
Regulatory B cell (Breg) counts were quantified by flow cytometry.
results: Phenotypic analyses showed an early expansion of transitional B cells, 
followed by a late expansion of the mature naive subset and decrease in plasmablasts 
and memory B cells. These anomalies are similar to those encountered in SSc patients. 
Functional analyses revealed a B-cell overproduction of pro-inflammatory cytokines 
(IL-6 and CCL3) and an impairment of their anti-inflammatory capacities (decreased 
production of IL-10 and TGF-β, reduced levels of Bregs) at the early inflammatory stage; 
and an overproduction of pro-fibrotic cytokines (TGF-β and IL-6) at the late fibrotic stage. 
These results approximate the anomalies observed in human SSc.
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inTrODUcTiOn
Systemic sclerosis (SSc) is a rare and severe condition classified 
within the connective tissue diseases. It is characterized by the 
progressive development of fibrosis in the skin and/or the inter-
nal organs such as lungs, digestive tract, and heart (1), impacting 
on vital and functional prognoses (2–5).
Systemic sclerosis pathophysiology is complex and only par-
tially elucidated (6). It combines, to different degrees, a fibrotic 
(excessive synthesis of collagen fibers by activated fibroblasts), 
vascular (microangiopathy), and immunological (dysregulation 
of cellular and humoral immune systems) components. Among 
the different immunity actors involved in SSc, the almost-constant 
presence of autoantibodies and hypergammaglobulinemia has 
long suggested a potential implication of B cells in the pathogen-
esis of the disease (7).
Recent data reinforce this hypothesis. Several works have 
shown alterations in B cell homeostasis and function in SSc 
patients. For example, there is a decrease in circulating memory 
B cell counts and an increase in naive B cell counts (8–12). 
Other teams have documented an enhanced secretion of pro-
inflammatory cytokines [such as interleukin (IL)-6], a reduced 
production of anti-inflammatory cytokines (such as IL-10), and 
a decrease in circulating regulatory B cell (Breg) counts (9–11, 
13–15). In SSc patients, B cells have also been shown to induce 
pro-fibrotic characteristics in dermal fibroblasts (16). Finally, 
B cell-targeted therapeutic strategies like anti-CD20 antibodies 
have been suggested to be effective in this disease (13).
Overall, B cells appear to have an important role in SSc 
pathophysiology beyond the classical production of autoanti-
bodies. A better description of B cell alterations in this disease, 
as well as animal models successfully recapitulating them, are 
therefore mandatory to further understand their pathogenic role 
and develop new therapeutic approaches. However, data on the 
modifications in B cell subset distribution and functional proper-
ties in animal models of SSc are scarce. Moreover, no study has 
ever considered a possible variation in B cell involvement during 
the course of SSc. This is of peculiar importance since several 
works have suggested that B cell-targeted therapeutic strategies 
may have different effects whether they are started at an early or 
late stage of the disease (17–20).
To address these issues, we used a novel murine model of 
SSc in which daily intradermal injections of hypochlorous acid 
(HOCl) induce a systemic fibrosis (21). We studied the modifica-
tions in B cell homeostasis, both at a phenotypic (B cell subsets 
distribution) and functional (cytokine production and interac-
tion with fibroblasts) level, at different time points during the 
course of the experimental disease.
aniMals anD MeThODs
induction of the experimental Disease
Animals
Six-week-old female BALB/c mice (Janvier Labs) were used in all 
experiments. Animals were housed in a specific pathogen-free 
facility, within autoclaved ventilated cages with sterile food and 
water ad  libitum, under constant room temperature and with 
12-h day–night cycles. This study was carried out in accordance 
with the local and national guidelines (directive #68/609 CEE). 
The protocol was approved by the Regional Ethics Committee on 
Animal Experimentation.
Experimental Procedure
Experimental SSc was induced by daily intradermal injections of 
300 µl of an HOCl-generating solution into the shaved backs of 
mice, using a 27-gauge needle and a 1-ml syringe, as previously 
described (21). The HOCl-generating solution was extempo-
raneously prepared by adding NaClO solution (9.6% as active 
chlorine) to a 100 mM KH2PO4 solution (pH 6.2). The NaClO 
amount was determined by measuring the optical density (OD) 
of the solution at 280  nm, and then adjusted to obtain an OD 
between 0.7 and 0.9. Control mice received injections of 300 µl of 
sterilized phosphate-buffered saline (PBS).
Sample Collection
Mice were sacrificed by cervical dislocation under deep CO2 
anesthesia at either day 21 (early stage) or day 42 (late stage) after 
the first injection. All samples were collected at the time of eutha-
nasia. Skin samples were collected near the injection site, and 
either immediately frozen and stored at −80°C (for biomolecular 
analyses), or fixed in a fresh 4% paraformaldehyde/PBS solution 
and embedded in paraffin (for histological and immunohisto-
chemical analyses). Whole spleens were immediately dissected 
to create a spleen cell suspension, filtered on a 70-µm nylon 
mesh and depleted in erythrocytes using an appropriate lysing 
buffer (Red Blood Cell Lysing Buffer Hybri-Max, cat. #R7757, 
Sigma-Aldrich). Blood samples were collected by retro-orbital 
puncture, set aside for clotting for 30 min, then centrifuged, and 
stored at −80°C.
conclusion: This work reports the existence of anomalies in B cell homeostasis and 
functional properties in an animal model of SSc that approximate those displayed by 
SSc patients. These anomalies vary over the course of the disease, which pleads for 
their participation in inflammatory and fibrotic events. This makes the HOCl mouse 
a relevant experimental model for the study of B cells, and therefore, B-cell-targeted 
therapies in SSc.
Keywords: systemic sclerosis, B cell, regulatory B cells, interleukin-6, interleukin-10, animal model
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FigUre 1 | continued 
evaluation of skin fibrosis in phosphate-buffered saline (PBs) and hOcl mice. To confirm the proper induction of the experimental disease, skin fibrosis was 
assessed by different methods in PBS and HOCl mice at day 42 after the beginning of the protocol. (a) Skin fold thickness (mm) measured sequentially by caliper 
(n = 20–26 per group). (B,c) Representative images of skin sections stained with May-Grünwald–Giemsa coloration from PBS [(B); 10×] and HOCl [(c); 10×] mice, 
showing dermal thickening in the HOCl mouse. (D) Dermal thickness measured on skin sections (n = 10–12 per group). Results are expressed as fold changes 
compared to the PBS group. (e) Hydroxyproline content in 6-mm skin punch biopsies (n = 7–8 per group). Results are expressed as fold changes compared to the 
PBS group. (F,g) Representative images of skin sections stained with picrosirius-red coloration from PBS [(F); 10×] and HOCl [(g); 10×] mice, showing collagen 
deposition in the HOCl mouse. (h) Collagen deposition total surface measured on skin sections (n = 10–12 per group). Results are expressed as fold changes 
compared to the PBS group. (i) Representative images of skin sections immunostained with DAPI alone (top row), DAPI and anti-α-smooth muscle actin (α-SMA) 
antibody (middle row), or DAPI and isotype control (bottom row) from PBS (left column) and HOCl (center and right columns) mice, showing expression of α-SMA in 
the HOCl mouse.
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evaluation of the experimental Disease
Measurement of Skin Fold Thickness
Skin fold thickness was assessed with a caliper by averaging the 
measure of two different locations near the injection site, twice a 
week until sacrifice.
Histological Evaluation
Skin samples embedded in paraffin were sliced into serial 4-µm 
sections. Dermal thickness at the injection site was assessed by 
performing a May-Grünwald–Giemsa (MGG) staining and 
measuring the distance between the epidermal–dermal junction 
and the dermal–subcutaneous fat junction at a 40-fold magni-
fication using the ImageJ morphometic software (U.S. National 
Institute of Health) (22). Ten random measurements per section 
were performed by two blinded investigators and averaged for 
each section. Collagen deposition in the skin was evaluated by 
performing a picrosirius-red staining and delineating the stained 
area using a color deconvolution method (23). This allowed a pre-
cise quantification of the total area occupied by collagen deposits 
in each section. Expression of α-smooth muscle actin (α-SMA) 
in the skin was assessed by immunofluorescence with a specific 
anti-α-SMA antibody (clone 1A4, cat. #ab7817, Abcam) coupled 
with DAPI (1:1,000-fold dilution, Thermo Fischer Scientific). 
Non-specific binding was appreciated using an isotype control 
antibody. Protein visualization was performed by using a specific 
Alexa Fluor 488 goat anti-rabbit antibody.
Measurement of Hydroxyproline Content
Collagen content was assessed by using a colorimetric 
Hydroxyprolin Kit Assay (Sigma-Aldrich) according to the 
manufacturer’s protocol. Briefly, approximately 10  mg of skin 
were homogenized in 100 ml of water and hydrolyzed at 120°C 
for 3  h in an equal volume of concentrated hydrochloric acid 
(HCl, 12 M). Then, a colorimetric product, visualized at 560 nm 
and proportional to the hydroxyproline content, was generated 
by reaction of oxidized hydroxyproline in each sample with 
4-(Dimethylamino)benzaldehyde.
Quantification of Fibrosis, Inflammation, and 
Proliferation Markers RNA Expression in Skin Samples
Approximately 0.5 cm of frozen skin samples were minced and 
mechanically homogenized. Then, total RNA was extracted with 
a Nucleospin RNA kit (Macherey-Nagel, Hoerdt, France) and 
eluted in RNAse-free water. The purity of RNA was evaluated by 
UV spectroscopy on a Nanodrop system from 220 to 350  nm. 
Then, 1 µg of total RNA was used to obtain single-stranded cDNA 
by using a specific Reverse Transcription Kit (Thermo Fisher 
Scientific) according to the manufacturer’s protocol. Quantitative 
RT-PCR was performed by using LightCycler FastStart DNA 
Master SYBR Green I (Thermo Fisher Scientific), according 
to the manufacturer’s protocol. Primers sets include TGFB for 
transforming growth factor (TGF)-β1, Acta2 for α-SMA, Fn1 
for Fibronectin, COL1a1 for Collagen I-1III, Il-6 for IL-6, Il-1b 
for IL-1β, tnfa for tumor necrosis factor (TNF)-α, and Pcna 
for proliferating cell nuclear antigen (PCNA). Sequences and 
relative NCBI references for each gene are listed in Table S1 in 
Supplementary Material. All samples were amplified in duplicate. 
DNA quantification was expressed as critical threshold cycle (Ct) 
value, or rather the cycle number at which the DNA amplification 
was first detected. Relative gene expression value was calculated as 
E = 2−ΔCt, where ΔCt is the difference in crossing points between 
GAPDH and each gene.
Phenotypic evaluation of B cells
Flow Cytometry
Immediately after collection, spleen cells were counted using an 
automated method (Flow-Count Fluorospheres, cat. #7547053, 
Beckman Coulter); and their viability was assessed with pro-
pidium iodide staining. Approximately 1 million spleen cells 
were incubated with mouse anti-Fc receptor antibody (FcBlock, 
clone 2.4G2; cat. #553142, BD Biosciences) for 15  min at 4°C 
protected from light to limit non-specific antibody binding. They 
were next incubated with different antibody mixes for membrane 
staining (Table S2 in Supplementary Material) for 20 min at 4°C 
protected from light. Data were then acquired on a 3-laser cytom-
eter (Navios, Beckman Coulter) and analyzed with a dedicated 
software (Kaluza, Beckman Coulter).
Quantification of Serum B Cell-Activating Factor 
(BAFF) Levels
B cell-activating factor levels were assessed on serum samples 
in duplicate at a 1:3-dilution using an ELISA assay (Quantikine 
ELISA Mouse BAFF, cat. #MBLYS0, R&D systems), according to 
the manufacturer’s protocol.
Quantification of CD19 Expression in Skin Samples
CD19 expression in skin samples was assessed by immuno-
fluorescence using a specific anti-CD19 antibody (0.5  µg/ml, 
BioLegend) overnight at 4°C, coupled with DAPI (1:1,000-fold 
dilution, Thermo Fischer Scientific). Protein visualization was 
performed by using a specific Alexa Fluor 566 goat anti-mouse 
antibody incubated for 1 h at room temperature.
FigUre 2 | expression of fibrosis, inflammation, and proliferation markers in the skin of phosphate-buffered saline (PBs) and hOcl mice at day 21 
and day 42 of the protocol. mRNA levels of various markers of fibrosis [fibronectin (a), α-smooth muscle actin (α-SMA) (B), transforming growth factor (TGF)-β 
(c), collagen (D)], inflammation [tumor necrosis factor (TNF)-α (e), interleukin (IL)-1β (F), IL-6 (g)], and proliferation [proliferating cell nuclear antigen (PCNA) (h)], 
normalized to GAPDH and expressed as fold changes to PBS day 21 (for day-21 groups) or to PBS day 42 (for day-42 groups) (n = 15–24 per group).
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TaBle 1 | Phenotypic definitions of spleen cell and B cell subsets.
cell subsets abbreviation Phenotypic definition
spleen cell subsets
B cell / CD19+
T cell / CD3+
T CD4+ cell / CD3+ CD4+
T CD8+ cell / CD3+ CD8+
nK cell / CD335+
Monocyte–macrophage MM CD11b+ FSChi
B cell subsets
B2 cell B2 CD19+ B220hi
immature B cells
=Transitional B cell TR CD19+ B220hi CD93+
Type 1 transitional B cell T1 CD19+ B220hi CD93+ CD23− IgMhi
Type 2 transitional B cell T2 CD19+ B220hi CD93+ CD23+ IgMhi
Type 3 transitional B cell T3 CD19+ B220hi CD93+ CD23+ IgMlo
Marginal zone precursor B cell MZP CD19+ B220hi CD93−/+ CD23hi IgMhi CD21hi
Mature naive B cells CD19+ B220hi CD93−
Follicular B cell FO CD19+ B220hi CD93− CD23+ CD21lo/med
Follicular type I B cell FO-I CD19+ B220hi CD93− CD23+ CD21lo/med IgMlo
Follicular type II B cell FO-II CD19+ B220hi CD93− CD23+ CD21lo/med IgMhi
Marginal zone B cell MZ CD19+ B220hi CD93− CD23− CD21hi IgMhi
nature non-naïve B cells
Germinal center B cells GC CD19+ CD38− GL7+
Centroblasts CB CD19+ CD38− GL7+ CXCR4+
Centrocytes CC CD19+ CD38− GL7+ CXCR4−
Antibody-secreting cells ASC CD138hi CD19lo/−
Plasmablasts PB CD138hi CD19lo CD22+
Plasma cells PC CD138hi CD19lo/− CD22−
Memory B cells MemB CD19+ CD93− CD38+ IgM−
B1 cells B1 CD19+ B220lo CD23− CD43+ IgMhi
B1a B cells B1a CD19+ B220lo CD23− CD43+ IgMhi CD5+
B1b B cells B1b CD19+ B220lo CD23− CD43+ IgMhi CD5−
regulatory B cells
CD5+ CD1dhi B cells / CD19+ CD5+ CD1dhi
IL-10+ B cells B10 CD19+ IL-10+
CXCR, CXC-chemokine receptor; FSC, forward scatter; Ig, immunoglobulin; IL, interleukin.
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Functional evaluation of B cells
B Cell Sorting
Immediately after collection, B cells were isolated from sple-
nocytes using a negative magnetic bead-assisted sorting assay 
(EasySep Mouse Pan-B Cell Isolation Kit, cat. #19844, StemCell), 
according to the manufacturer’s protocol. B cell purity was always 
above 95% as assessed by flow cytometry.
Quantification of IL-6, CCL3, IL-10, and TGF-β 
RNA Expression in B Cells
Immediately after sorting, purified B cells were ultra-centrifuged, 
treated with lysis buffer (NucleoSpin RNA kit, Macherey-Nagel), 
and stored at −80°C. Quantification of IL-6, chemokine ligand 
(CCL) 3, IL-10, and TGF-β RNA expression in B cells was 
performed as detailed in Section “Quantification of Fibrosis, 
Inflammation, and Proliferation Markers RNA Expression in 
Skin Samples” (except that levels were normalized to GUSB).
Quantification of IL-6, IL-10, and CCL3 Protein 
Levels in B Cells
Immediately after sorting, purified B cells were seeded on a 
96-well plate (400,000 B cells per well) within complete medium 
[Roswell Park Memorial Institute (RPMI) 1640 medium contain-
ing 10% heat-inactivated fetal calf serum (FCS), 20 UI/ml penicil-
lin, 20 µg/ml streptomycin, 2 mM l-glutamin, 1 mM pyruvate, 
50 µM 2-mercaptoethanol, and 1% non-essential amino acids]. 
They were cultured during 48 h at 37°C in humidified atmosphere 
with 5% CO2 and stimulated either with lipopolysaccharide 
(LPS) (Escherichia coli serotype O127:B8, 10 µg/ml; cat. #L4516, 
Sigma-Aldrich), with LPS and anti-CD40 antibody (clone 
HM40/3, 2.5  µg/ml; cat. #553721, BD Biosciences), or without 
immunostimulation. After culture, supernatants were collected 
and immediately stored at −80°C.
Interleukin-6, IL-10, and CCL3 protein levels in superna-
tant samples were assessed in duplicate using ELISA assays 
(Quantikine ELISA Mouse IL-6, cat. #M6000B; Quantikine ELISA 
Mouse IL-10, cat. #M1000B; Quantikine ELISA Mouse CCL3, cat. 
#MMA00; R&D systems), at appropriate dilutions (1:10 for IL-6; 
1:1 for IL-10; 1:100 for CCL3). All experiments were conducted 
according to the manufacturer’s protocols.
IL-10 Intracellular Staining
Immediately after sorting, purified B cells were seeded on 
a 48-well plate (2 million B cells per well) within complete 
FigUre 3 | gating strategy used for identification of the main B cell subsets. Doublets were first excluded on an FSC-area/FSC-height dot-plot (not shown). 
Lymphocytes were then selected based on their size and internal complexity on a FSC/SSC dot-plot (not shown). B cells were next delimited on a CD19/open 
channel dot-plot and defined as CD19+ non-autofluorescent cells (not shown). B2 cells were identified as CD19+ B220hi cells on a CD19/B220 dot-plot gated on 
B cells (a). Transitional B cells were then selected as CD93+ cells (B) and divided into their three main subsets based on their expression of CD23 and IgM 
(c,D). Among mature B2 cells, defined as CD93− cells (B), follicular (FO) and marginal zone (MZ) B cells were separated based on their membrane levels of CD23 
and IgM (e). FO B cells were further divided into follicular type I (FO-I) and follicular type II (FO-II) depending on their expression levels of IgM (F). MZP B cells were 
identified as CD23hi cells within a gate containing CD21hi IgMhi B2 cells (g,h). MZP cells were then backgated out of the T2 and FO populations (D,F). B1 cells were 
identified as CD23− CD43+ cells among CD19+ B220hi cells (a,i). B1a cells were then separated from B1b cells based on their membrane expression of CD5 (J). 
FSC, forward scatter; Ig, immunoglobulin; SSC, side scatter.
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medium (RPMI 1640 medium containing 10% heat-inactivated 
FCS, 20  UI/ml penicillin, 20  µg/ml streptomycin, 2  mM 
l-glutamin, 1 mM pyruvate, 50 µM 2-mercaptoethanol, and 1% 
non-essential amino-acids). As previously described (24), they 
were cultured during 48  h at 37°C in humidified atmosphere 
with 5% CO2 and stimulated by anti-CD40 antibody (clone 
HM40/3, 1  µg/ml; cat. #553721, BD Biosciences). During the 
last 5  h of culture, LPS (E. coli serotype O111:B4, 10  µg/ml; 
cat. #L4391, Sigma-Aldrich), PMA (50  ng/ml, cat. #P8139, 
Sigma-Aldrich), ionomycin (500  ng/ml, cat. #I0634, Sigma-
Aldrich), and monensin (2 mM, cat. #00-4505-51, eBiosciences) 
were added to the culture medium to induce IL-10 expression 
and block exocytosis (24).
Interleukin-10 intracellular detection was performed as 
previously described (24). First, B cells were stained with a 
viability dye (Live/Dead Fixable Far Red Dead Cell Stain Kit, 
1:3,200-dilution, cat. #L10120, Life Technologies), saturated 
with an anti-Fc receptor antibody (FcBlock, clone 2.4G2; cat. 
FigUre 4 | Distribution of the main spleen cell subsets in phosphate-buffered saline (PBs) and hOcl mice at day 21 and day 42. Distribution of B cells 
(a), T cells (B), T CD4+ cells (c), T CD8+ cells (D), NK cells (e), and monocytes–macrophages (F) in absolute values expressed in cells (n = 12–17 per group).
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#553142, BD Biosciences) to prevent non-specific binding, and 
stained with an anti-CD19 antibody (Brillant Violet 510 Rat 
Anti-Mouse CD19, clone 1D3; cat. # 562956, BD Biosciences). 
Next they were fixed and permeabilized with the Cytofix/
Cytoperm kit (cat. #554722, BD Biosciences) according to 
the manufacturer’s protocol. Permeabilized cells were then 
stained with an anti-IL-10 antibody (PE Rat Anti-Mouse IL-10, 
clone JES5-16E3; cat. #554467, BD Biosciences). Data were 
acquired on a 3-laser cytometer (Navios, Beckman Coulter) 
and analyzed with a dedicated software (Kaluza, Beckman 
Coulter).
Fibroblasts–B Cells Coculture Experiments
Mouse embryonic fibroblast cells (BALB/c 3T3, ATCC clone 
A31) were purchased from American Type Culture Collection 
(ATCC; MD, USA). B cells were sorted as described in Section 
“B Cell Sorting.” Cells were cultured in complete medium (RPMI 
1640 medium containing 10% heat-inactivated FCS, 20  UI/ml 
penicillin, 20  µg/ml streptomycin). 3T3 fibroblasts (105 cells) 
alone, B cells (5 × 105 cells) alone, or cocultures were seeded in 
12-well plates for 72 h.
Quantification of fibrosis and proliferation markers RNA 
expression in fibroblasts was performed as detailed in Section 
FigUre 5 | Distribution of the main B cell subsets in phosphate-buffered saline (PBs) and hOcl mice at day 21 and day 42. Distribution of immature 
B cells and its main subsets (a), mature naive B cells and its main subsets (B), germinal center B cells and its main subsets (c), antibody-secreting cells and its 
main subsets (D), memory B cells (e), and B1 cells (F) in relative values expressed in percentages of CD19+ cells (except for ASC, PB, and PC expressed in 
percentages of total spleen cells) (n = 7–8 per group).
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“Quantification of Fibrosis, Inflammation, and Proliferation 
Markers RNA Expression in Skin Samples.”
statistical analysis
Multi-group comparisons were performed using Kruskall and 
Wallis non-parametric test. Whenever a significant difference 
was detected, Mann–Whitney test was used to compare each 
group by pair. All statistical analyses were performed on SPSS 
v22 (IBM) and GraphPad Prism v6 (GraphPad Software). 
Quantitative data were expressed as mean ± SEM. Significance 
was set at p < 0.05. In figures, levels of significance were pictured 
as follows: ****p ≤ 0.0001; ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, 
°p ≤ 0.20; and ns for p ≥ 0.20.
resUlTs
hOcl injections induce an experimental 
Disease Whose characteristics and 
course resemble human ssc
HOCl Intradermal Injections Induce Skin Fibrosis in 
Mice
In a first step, we wanted to confirm the validity of the 
experimental disease. Induction of skin fibrosis in HOCl mice 
was assessed through clinical, protein, and histological evalu-
ations (Figure  1). Thus, we observed a significant increase in 
the macroscopic skin fold in HOCl mice compared to PBS 
mice (p <  0.0001) (Figure  1A). Dermal thickness, measured 
on MGG-stained skin sections, was also significantly higher 
in the HOCl group than in the control group (p  <  0.0001) 
(Figures  1B–D). A higher amount of collagen fibers in 
skin sections of HOCl mice, compared to PBS mice, was 
observed by histological picrosirius-red staining (p <  0.0001) 
and confirmed by evaluation of the hydroxyproline content, 
which was significantly increased in HOCl mice (p  <  0.05) 
(Figures 1E–H). Finally, a consistent amount of α-SMA-positive 
cells on skin from HOCl mice was qualitatively appreciated by 
immunofluorescence, whereas PBS mice showed a very low 
number of α-SMA-expressing cells (Figure  1I). Overall, these 
results indicated the validity of the experimental disease, as 
previously described (21).
The Early Stage of the HOCl Model Displays More 
Inflammatory Features than the Late Stage
As human SSc usually evolves through an early inflamma-
tory stage and a late fibrotic stage, we wondered whether 
a similar phenomenon occurred during the course of 
the HOCl experimental disease. An evaluation of mRNA 
FigUre 6 | representative dot-plots of immature and mature B2 cells in phosphate-buffered saline (PBs) and hOcl mice at day 21 and day 42. 
Representative CD19/CD93 dot-plots gated on B cells from PBS (left column) and HOCl (right column) mice at day 21 (top row) and day 42 (bottom row), showing 
early expansion of the transitional subset and late expansion of the mature naïve cells in the HOCl mouse.
FigUre 7 | serum B cell-activating factor (BaFF) levels in phosphate-
buffered saline (PBs) and hOcl mice at day 21 and day 42. Results 
expressed in picograms per milliliter (n = 6–7 per group).
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expression profile of various fibrosis (fibronectin, α-SMA, 
collagen, TGF-β), inflammatory (TNF-α, IL-1β, IL-6), and 
proliferation (PCNA) markers in the skin of PBS and HOCl 
mice was thus performed at two different time points from 
the beginning of the protocol (day 21: early stage; day 42: late 
stage).
At day 21, we observed a significant increase in the mRNA 
expression of fibrotic, inflammatory, and proliferation mark-
ers in the HOCl mice compared to PBS mice (fibronectin: 
p <  0.0001; α-SMA: p =  0.0004; collagen: p <  0.0001; TGF-β: 
p = 0.01; TNF-α: p = 0.02; IL-1β: p < 0.0001; IL-6: p = 0.004; 
PCNA: p =  0.04) (Figure  2). At day 42, a significant increase 
in the mRNA levels of all pro-fibrotic proteins was still 
observed (fibronectin: p < 0.0001; α-SMA: p = 0.001; collagen: 
p <  0.0001; TGF-β: p =  0.0001). However, among inflamma-
tory and proliferation markers, only TNF-α and IL-1β were 
differentially expressed (p = 0.0006 and p = 0.0005, respectively); 
there was no longer a significant difference in the production 
of IL-6 (p =  0.67) and PCNA (p =  0.31) (Figure  2). Overall, 
these results suggested that the early stage of the experimental 
disease displays more inflammatory and proliferative features 
than the late stage, which mimics to some extent the natural 
course of human SSc.
splenic B cell homeostasis is altered 
in hOcl Mice
Splenic B Cell Subset Distribution Is Modified in 
HOCl Mice and Varies over Time
Several works have reported disturbances in B cell homeostasis 
in SSc, especially in B cell subset distribution. We wondered if 
FigUre 8 | representative images of skin sections immunostained for cD19 in phosphate-buffered saline (PBs) and hOcl mice at day 21 and day 
42. Representative images of PBS skin (top row), HOCl skin at day 21 (middle row), and HOCl skin at day 42 (bottom row) immunostained with DAPI (left column), 
with anti-CD19 antibody (middle column), and with both (right column) (n = 5 per group).
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such anomalies existed in the HOCl model, and if so, how they 
would evolve during the course of the experimental disease. We 
compared the main leukocyte and B cell subsets in the spleens of 
HOCl and PBS mice, at the early and late stages of the disease. 
The phenotypic definitions and gating strategy used for their 
identification are detailed in Table 1 and Figure 3, respectively.
Regarding total splenic B cell counts, we observed a significant 
decrease in HOCl mice at day 21 (p = 0.007), but no difference 
between the two groups at day 42 (p =  0.53) (Figure  4A). A 
similar trend was noted for the other splenic lymphocyte subsets, 
with a significant reduction in T CD4+, T CD8+, and NK cells at 
the early stage, and no difference at the late stage (Figures 4B–E). 
Monocyte and macrophage counts were equivalent at both stages 
of the disease (Figure 4F).
Regarding immature B cell subsets (Figures  5A and 6), 
there was a trend for an increase in transitional forms at day 21 
(p = 0.07) and a non-significant decrease at day 42 (p = 0.33) in 
HOCl mice. These anomalies reached statistical significance for 
transitional type 2 (T2) B cells at the early stage (p = 0.009) and 
transitional type 3 (T3) B cells at the late stage (p = 0.03).
Regarding mature naive subsets (Figures 5B and 6), the oppo-
site phenomenon was noted, with a trend for a decrease at day 21 
(p = 0.07) and a significant increase (p = 0.04) at day 42. These 
anomalies were mainly carried by the major mature naive subset, 
called follicular (FO) B cells (p = 0.07 at day 21; p = 0.02 at day 
42). Interestingly though, the early FO decrease was essentially 
explained by the follicular type I B cells (p = 0.05) whereas the 
late FO increase was mostly supported by the follicular type II 
B cells (p = 0.0003). Conversely, the minor mature naive subset, 
named marginal zone B cells, was non-significantly decreased at 
both stages of the disease (p = 0.05 at day 21; p = 0.10 at day 42).
Regarding non-naive B cell subsets, germinal center B cell 
counts were similar in both groups at both time points, even when 
considering the centroblast and centrocyte subsets (Figure 5C). 
Although there was no difference in antibody-secreting cell 
and plasma cell counts between the two groups, a significant 
decrease in the plasmablast subset was noted at day 42 (p = 0.003) 
(Figure  5D). Switched memory B cells were also decreased in 
HOCl mice at both stages of the disease (p = 0.0007 at day 21; 
p = 0.001 at day 42) (Figure 5E).
Regarding B1 B cells (Figure 5F), we observed a trend for a 
decrease in HOCl mice at day 42 (p = 0.09) that reached signifi-
cance for the B1a subset (p = 0.04).
Overall, these results confirmed that the HOCl model displays 
alterations in splenic B cell subset distribution (early expansion of 
transitional B cells; late expansion of the mature naive subset; and 
decrease in plasmablasts and memory B cells).
Alterations in B Cell Subset Homeostasis Are 
Independent of BAFF
B cell homeostasis and maturation are regulated by a large 
number of factors among which survival signals (such as BAFF) 
play a critical role. Since serum BAFF levels are increased in SSc 
patients, we wondered if it could contribute to the alterations in 
B cell subset distribution observed in the HOCl model. However, 
serum BAFF levels were identical in both groups at both time 
points (Figure 7), suggesting that this cytokine does not partici-
pate in these anomalies.
12
Sanges et al. B Cells in SSc Model
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 53
HOCl Skin Is Infiltrated by B Cells at the Late Stage
Next we wondered if anomalies in B cell homeostasis were also 
observed outside the spleen and within disease-targeted organs. 
To do so, we assessed CD19 expression in skin samples from 
the two groups and found a significant B cell infiltration in 
HOCl skin at day 42, but no difference with PBS mice at day 21 
(Figure 8).
Taken together with our previous results, these findings might 
indicate that B cells could be recruited from the spleen to infiltrate 
the skin.
splenic B cell Functional Properties 
are altered in hOcl Mice
As human SSc B cells display functional anomalies that contribute 
to the pathogenesis of the disease, we next wondered whether the 
same holds true for HOCl splenic B cells. Therefore, we sought 
to investigate their pro-inflammatory, anti-inflammatory, and 
pro-fibrotic properties by studying their production of various 
cytokines.
Splenic B Cell Production of Pro-inflammatory 
Cytokines Is Increased in HOCl Mice
Based on data from a preliminary work (not shown), we selected 
two candidate proteins, IL-6 and CCL3, to assess the pro-
inflammatory properties of B cells in the HOCl model.
First we measured IL-6 and CCL3 mRNA levels in splenic 
B cells ex vivo (just after collection and sorting). IL-6 mRNA 
levels did not differ at day 21 (p  =  0.83); but there was a 
trend for a significant increase in the HOCl group at day 42 
(p =  0.06) (Figure  9A). CCL3 production was significantly 
higher in HOCl mice at both time points (p =  0.02 in both 
cases) (Figure 10A).
As to further explore these anomalies, we then studied the 
secretion of IL-6 and CCL3 in splenic B cells cultured with vari-
ous stimulation conditions. Without immunostimulation, there 
was only negligible basal secretion of both cytokines at both 
time points. When stimulated by LPS alone or with anti-CD40 
antibody, HOCl B cells produced more IL-6 and CCL3 than the 
control group at both time points (Figures  9B and 10B). This 
FigUre 9 | interleukin (il)-6 production by splenic B cells in phosphate-buffered saline (PBs) and hOcl mice at day 21 and day 42. (a) IL-6 mRNA 
levels in splenic B cells after collection and sorting, normalized to GUSB and expressed as fold changes to PBS day 21 for day-21 groups (top row), and to PBS day 
42 for day-42 groups (bottom row) (n = 4–6 per group). (B) IL-6 supernatant levels after culture of splenic B cells for 48 h with various stimulation conditions [none, 
lipopolysaccharide (LPS), LPS + anti-CD40 antibody] at day 21 (top row) and day 42 (bottom row), expressed in picograms per milliliter (n = 6–8 per group).
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increase always reached statistical significance, except for CCL3 
at day 42 with LPS stimulation (p = 0.18) (Figures 9B and 10B). 
IL-6 and CCL3 levels in HOCl B cells did not differ between day 
21 and day 42 in both stimulation conditions.
Overall, these results suggested that splenic B cells display 
pro-inflammatory features in HOCl mice.
B Cell Production of IL-10 and Breg Levels Are 
Reduced in HOCl Mice
As there is a growing body of evidence implicating B cells in 
immune response suppression and regulatory processes in auto-
immune diseases (25), we next studied the anti-inflammatory 
properties of B cells in the HOCl model. We first assessed the 
production of IL-10, a potent anti-inflammatory cytokine, by 
splenic B cells. When measured ex vivo, IL-10 mRNA levels were 
significantly lower in HOCl B cells at day 21 (p = 0.01) but identical 
at day 42 (p = 0.82) (Figure 11A). After culture and stimulation 
by LPS alone or with anti-CD40 antibody, similar results were 
found: a significant decrease in IL-10 secretion by HOCl B cells 
at day 21 (p = 0.002 with both stimulations) and identical levels 
at day 42 (p = 0.51 with LPS and p = 0.47 with LPS + anti-CD40 
antibody) (Figure  11B). Of note, without immunostimulation, 
IL-10 production by HOCl B cells was significantly higher than 
PBS mice but at negligible levels.
Within the B cell compartment, the main source of IL-10 
production is Bregs, a recently identified subset endowed with 
anti-inflammatory properties (25). In mice, Bregs are formally 
identified as CD19+ IL-10+ cells (“B10” cells) and mostly con-
tained within the CD19+ CD5+ CD1dhi subset (24). To confirm 
our previous results, we next measured splenic Breg counts 
using both phenotypic definitions. Here again, we made similar 
observations: a significant decrease in B10 cells (p = 0.004) and 
in CD5+ CD1dhi B cells (p =  0.006) in HOCl mice at day 21; 
but no difference at day 42 (p = 0.39 and p = 0.24, respectively) 
(Figures 11C,D and 12).
Overall, these results suggested that B cell anti-inflammatory 
properties are impaired at the early inflammatory stage of the 
experimental disease.
FigUre 10 | ccl3 production by splenic B cells in phosphate-buffered saline (PBs) and hOcl mice at day 21 and day 42. (a) CCL3 mRNA levels in 
splenic B cells after collection and sorting, normalized to GUSB and expressed as fold changes to PBS day 21 for day-21 groups (top row), and to PBS day 42 for 
day-42 groups (bottom row) (n = 4–6 per group). (B) CCL3 supernatant levels after culture of splenic B cells for 48 h with various stimulation conditions [none, 
lipopolysaccharide (LPS), LPS + anti-CD40 antibody] at day 21 (top row) and day 42 (bottom row), expressed in picograms per milliliter (n = 6–8 per group).
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FigUre 11 | interleukin (il)-10 production and regulatory B cell levels in phosphate-buffered saline (PBs) and hOcl mice at day 21 and day 42. 
(a) IL-10 mRNA levels in splenic B cells after collection and sorting, normalized to GUSB and expressed as fold changes to PBS day 21 for day-21 groups (left 
column), and to PBS day 42 for day-42 groups (right column) (n = 4–6 per group). (B) IL-10 supernatant levels after culture of splenic B cells for 48 h with various 
stimulation conditions [none, lipopolysaccharide (LPS), LPS + anti-CD40 antibody] at day 21 (left column) and day 42 (right column), expressed in picograms per 
milliliter (n = 6–8 per group). (c) Proportion of B10 cells identified by intracellular IL-10 detection at day 21 (left column) and day 42 (right column), expressed as 
percentages of CD19+ cells (n = 10 per group). (D) Proportion of CD5+ CD1dhi B cells identified by conventional membrane staining at day 21 (left column) and day 
42 (right column), expressed as percentages of CD19+ cells (n = 7–8 per group).
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FigUre 12 | representative dot-plots of B10 cells in phosphate-buffered saline (PBs) and hOcl mice at day 21. Representative CD19/interleukin (IL)-10 
dot-plots gated on B cells from PBS (middle column) and HOCl (left column) mice at day 21, showing a decreased proportion of B10 cells in the HOCl mouse.
Splenic B Cells Display Pro-Fibrotic Properties in 
HOCl Mice
As B cells have been shown to contribute to fibrogenesis in 
patients with SSc (16), we then wondered if similar findings could 
be made in our experimental model. We measured mRNA levels 
of TGF-β, a major pro-fibrotic cytokine, in HOCl and PBS splenic 
B cells at both time points. TGF-β production by HOCl B cells 
was found decreased at day 21 (p = 0.03) but increased at day 42 
(p = 0.02) when compared to the control group (Figure 13A).
Finally, we next studied if B cells could directly induce a 
pro-fibrotic phenotype in fibroblasts. We found that fibroblasts 
cocultured with HOCl B cells produced higher levels of α-SMA 
(p = 0.007), collagen (p = 0.0008), and fibronectin (p = 0.009) 
than when cultured alone (Figures  13B–D). Coculture with 
HOCl B cells also triggered fibroblast proliferation as we observed 
a significant increase in PCNA (p = 0.006) (Figure 13E). These 
mRNA levels tended to be higher in fibroblasts cocultured 
with HOCl B cells than with PBS B cells (p = 0.08 for α-SMA, 
p = 0.09 for collagen, p = 0.15 for fibronectin, p = 0.06 for PCNA) 
(Figures 13B–E). Further studies are warranted to confirm these 
results.
Overall, these observations suggest that B cells also display 
pro-fibrotic properties in HOCl mice.
DiscUssiOn
To our knowledge, this is the first study to focus on a thorough 
examination of B cells in an animal model of SSc. Our results 
can be summarized as follows: (1) HOCl mice exhibit alterations 
in B cell subset distribution (early expansion of transitional B 
cells; late expansion of the mature naive subset; and decrease in 
plasmablasts and memory B cells); (2) HOCl splenic B cells dis-
play enhanced pro-inflammatory features (increased production 
of IL-6 and CCL3); (3) HOCl splenic B cell anti-inflammatory 
properties are impaired at the early inflammatory stage of the 
experimental disease (decreased IL-10 production and Breg 
counts); (4) HOCl splenic B cells may contribute to fibrogenesis 
by producing TGF-β and inducing a pro-fibrotic phenotype in 
fibroblasts; and (5) these anomalies are dynamic and vary over 
the course of the experimental disease.
Perturbations in B cell homeostasis are well documented 
in human SSc (8–12) but have been rarely assessed in animal 
models. Aside from the present study, splenic B cell counts 
and subset distribution have only been examined in tight-skin 
(Tsk) mice, where they were found similar to controls (26). This 
makes our work the first to identify alterations in B cell subset 
homeostasis in an experimental model of SSc. More importantly, 
the anomalies found in HOCl mice are close to those reported in 
human SSc. Just as splenic B cell counts are decreased during the 
early active stage of the experimental protocol, circulating B cell 
lymphopenia is associated with disease activity and severity in 
SSc patients (27, 28). Characteristic B cell subset modifications in 
human SSc consist in an expansion of mature naive B cells and a 
depletion in memory B cells and plasmablasts (8–12), all of which 
were observed in HOCl mice in our study. Overall, it appears that 
the HOCl model correctly approximates the perturbations in B 
cell homeostasis observed in human SSc. These splenic anomalies 
could also bear a pathophysiological relevance, as they are associ-
ated with a B cell infiltration in the skin at the late stage.
B cell functional anomalies, and especially abnormal cytokine 
production, have been reported in SSc patients and experimental 
models (9–12, 14, 16, 26, 29–31). In both contexts, B cells display 
enhanced pro-inflammatory and pro-fibrotic properties, as well 
as impaired immune suppression capabilities, which pleads for a 
significant role in the pathogenesis of the disease and makes them 
a relevant therapeutic target. HOCl splenic B cells were found to 
produce higher levels of IL-6 than PBS mice. This confirms results 
from previous works that also documented an increased B cell 
secretion of IL-6 in this model (32), in the Tsk and bleomycin-
induced SSc models (26, 29–31) and in human SSc (14). B cell 
overproduction of IL-6 is a significant feature of SSc pathogen-
esis, since treatment by rituximab induces a decrease in both IL-6 
serum levels and skin fibrosis in SSc patients (13). Our study 
confirms that the HOCl model replicates this important charac-
teristic of SSc B cells. Besides IL-6, we observe in our study a B cell 
overproduction of CCL3, a chemokine that promotes macrophage 
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FigUre 13 | evaluation of pro-fibrotic properties of splenic B cells in phosphate-buffered saline (PBs) and hOcl mice at day 21 and day 42. (a) 
Transforming growth factor (TGF)-β mRNA levels in splenic B cells after collection and sorting, normalized to GUSB and expressed as fold changes to PBS day 21 
for day-21 groups (left column), and to PBS day 42 for day-42 groups (right column) (n = 4–6 per group). (B–e) mRNA levels of markers of fibrosis [α-smooth 
muscle actin (α-SMA) (B), collagen (c), and fibronectin (D)] and proliferation [proliferating cell nuclear antigen (PCNA) (e)] in 3T3 fibroblasts cultured alone (control; 
gray bars), with day-42 PBS B cells (white bars) or with day-42 HOCl B cells (black bars). Results normalized to GAPDH and expressed as fold changes to control 
(n = 5–8 per group).
migration within inflammatory sites, which has never been 
described either in SSc models or patients. Interestingly, CCL3 
levels are increased in the serum and bronchoalveolar fluid of SSc 
patients and associated with alveolitis and interstitial lung disease 
(33–35). As activated CD11b+ macrophages are present in the 
skin of HOCl mice (36), one could hypothesize that production 
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of CCL3 by B cells may participate to their recruitment and 
activation in lesioned sites. Interestingly, B cell overproduction of 
IL-6 and CCL3 is documented not only at the early inflammatory 
stage, but also at the late fibrotic stage of the experimental disease. 
As sustained inflammation ultimately leads to fibrogenesis, this 
could indicate a dual role of these cytokines over time (initially 
pro-inflammatory and eventually pro-fibrotic).
A crucial result of our work is the documentation of impaired 
anti-inflammatory properties in HOCl B cells at the early stage of 
the protocol. Using multiple methods, we found a decrease in B 
cell production of IL-10 and a reduction in Breg counts in HOCl 
spleens. Similar observations were made in human SSc (9–11), 
which makes it yet another feature of SSc B cells adequately 
reproduced in this model. Interestingly, circulating Breg counts 
are inversely correlated with C-reactive protein serum levels, 
suggesting that, just like in HOCl mice, reduction in Breg counts 
occurs during the inflammatory stage of the disease (11). Bregs 
are currently the subject of intense research, as their therapeutic 
administration in several animal models of autoimmune diseases 
yielded promising results (25). Their potential as a treatment 
option in SSc remains, however, to be explored.
Aside from their role in inflammation, several studies sug-
gested that B cells also participate in fibrogenesis during SSc. In 
this work, we found an increased B cell production of TGF-β at 
the late stage, confirming previous results in this model (32) and 
in others (30, 31). In SSc patients, B cells are able to induce pro-
duction of extracellular matrix components by dermal fibroblasts 
(16). Preliminary data presented in this work tend to suggest that 
a similar phenomenon occurs in HOCl mice, but further studies 
are warranted to confirm this observation. Interestingly, we also 
observed a decreased TGF-β production by B cells at the early 
stage. Aside from its potent pro-fibrotic effect, TGF-β is also 
involved in immune response regulation (37). This result could 
suggest pleiotropic effects for TGF-β in this model, depending on 
the stage of the experimental disease.
Overall, our results suggest that B cells could participate in the 
early inflammatory events of the experimental protocol through 
an overproduction of pro-inflammatory cytokines (IL-6 and 
CCL3) and an impairment of their anti-inflammatory capabili-
ties (decreased production of IL-10 and TGF-β, reduced levels of 
Bregs); and in the late fibrotic events through a cytokine over-
production (TGF-β and IL-6) which may induce a pro-fibrotic 
phenotype in fibroblasts. These functional anomalies are close to 
those encountered in human SSc.
Our work has some limitations. Most of our results are descrip-
tive in nature, which does not allow for a definitive assessment of 
their relevance in the pathogenesis of the experimental disease. 
Further studies, either functional and/or mechanistical in design 
(such as complete B cell or specific subset depletions), are war-
ranted to draw definitive conclusions.
In conclusion, this work reports, for the first time in an SSc 
model, the existence of anomalies in B cell homeostasis and 
functional properties that approximate those displayed by SSc 
patients. Furthermore, it suggests that these anomalies vary 
over the course of the disease, which has never been considered 
before and may contribute to the inflammatory and fibrotic 
events observed in SSc. This makes the HOCl mouse a relevant 
experimental model for the study of B cells, and especially B cell-
targeted therapies, in SSc.
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